Neuropiln 1 (Nrp1) Modulation for Immune System Control (SJ-13-0012)



Technology Name
(St. Jude Reference #)
Neuropiln 1 (Nrp1) Modulation for Immune System (SJ-13-0012)
Description Boosting the ability of regulatory T cells by blocking an effective anti-tumor immune response led to the elimination or dramatic reduction of melanoma by the immune system in mice, without causing the autoimmune and inflammatory problems often associated with current cancer-treatment efforts that target immune regulators. The mechanism is built around two proteins. One, semaphorin-4a (Sema4a), is carried on the surface of various immune cells that can spark inflammation. The other, neuropilin-1 (Nrp1), is carried on the surface of regulatory T cells. For a full press release about this technology, visit http://www.stjude.org/vignali-tregs
Keywords Regulatory T cell (Treg), Neuropiln 1 (Nrp1), Semaphorin-4a (Sema4a), tumor-induced tolerance, tumor resistance, autoimmune, inflammation, cancer, immunotherapeutic
Granted Patents or Published Applications  
Related Scientific References 'Regulatory T cell stability is maintained by a neuropilin-1:semaphorin-4a axis' is published on Nature.com: http://dx.doi.org/10.1038/nature12428. (Abstracts are available to everyone, full text only to subscribers; relevant references are cited in the paper and can be provided on request).
Licensing Opportunities We are currently seeking nonexclusive licensing opportunities in all fields for the development of this technology.
   

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: August 2013

Sign up for licensing bulletins

or browse our technology